Acadia Investor Says Officers Overhyped Drug's Prospects

By Emilie Ruscoe · December 19, 2023, 7:39 PM EST

An investor in biopharmaceutical company Acadia Pharmaceuticals Inc. has filed a derivative shareholder suit against the company's brass in San Diego federal court alleging the executives misrepresented its chances of receiving...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Kanner et al v. Biggar et al

Case Number

Court

California Southern

Nature of Suit

Stockholders Suits

Date Filed

December 15, 2023

Recent Articles By Emilie

May 14, 2024
Vein Tech Maker Faces Investor Suit Over DOJ Kickback Probe
April 19, 2024
AI Health Data Co. Faces Investor Suit Over Accounting Issues
April 18, 2024
Doximity Faces Investor Suit Over Slashed Revenue Hopes
March 15, 2024
'Cobra Venom' Painkiller Co. Inks Deal To Settle SEC Claims
February 21, 2024
Former Exec Convicted Of Medtronic Insider Trading Scheme
February 12, 2024
Investors Win Class Cert. Against Failed COVID Test Maker
January 22, 2024
Investors Sue Biopharma Co. After Clinical Trial Data Toss
December 06, 2023
Cancer Test Co. Overpromised Insurer Coverage, Suit Says
November 27, 2023
Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit
October 03, 2023
Pomerantz Plucks $5.5M Fee For Clover Health Investor Deal